Annovis Launches 3-Year Parkinson’s Study to Test Long-Term Promise of Drug
MALVERN, PA — Annovis Bio, Inc. (NYSE: ANVS) said it will begin enrolling patients in January 2026 in a large, long-term study designed to assess whether its experimental Parkinson’s disease …
Annovis Launches 3-Year Parkinson’s Study to Test Long-Term Promise of Drug Read More